NCT07049926View on ClinicalTrials.gov

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 20, 2025

Primary Completion Date

October 26, 2031

Study Completion Date

October 26, 2031

Conditions
Renal Cell Carcinoma
Interventions
DRUG

Belzutifan

Oral Tablet

DRUG

Zanzalintinib

Oral Tablet

Trial Locations (6)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center ( Site 5002), New York

94158

RECRUITING

UCSF Medical Center at Mission Bay ( Site 5008), San Francisco

3109601

RECRUITING

Rambam Health Care Campus ( Site 5500), Haifa

4941492

RECRUITING

Rabin Medical Center ( Site 5502), Petah Tikva

5265601

RECRUITING

Sheba Medical Center ( Site 5501), Ramat Gan

6423906

RECRUITING

Sourasky Medical Center ( Site 5503), Tel Aviv

Sponsors

Collaborators (1)

Exelixis
All Listed Sponsors
collaborator

Exelixis

INDUSTRY

lead

Merck Sharp & Dohme LLC

INDUSTRY